| Literature DB >> 29121664 |
Ji-Hoon Nam1, Dae-Hwan Kim1, Je-Hyun Yoo1, Ji-Hyo Hwang2, Jun-Dong Chang3.
Abstract
BACKGROUND: Elderly patients undergoing hip fracture surgery (HFS) are at increased risk of postoperative venous thromboembolism (VTE). To reduce this risk, combined postoperative mechanical and chemical thromboprophylaxis has been routinely performed after HFS in these patients. This retrospective case-control study was conducted to evaluate the additional effectiveness of preoperative mechanical thromboprophylaxis for the prevention of VTE following HFS in elderly patients.Entities:
Mesh:
Year: 2017 PMID: 29121664 PMCID: PMC5679592 DOI: 10.1371/journal.pone.0187337
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flowchart demonstrating patient selection and exclusions.
Demographic and perioperative data in both two groups.
| Variables | Control group (n = 404) | Study group (n = 135) | p-value | |
|---|---|---|---|---|
| Gender | 0.855 | |||
| Male | 111 (28%) | 36 (27%) | ||
| Female | 293 (72%) | 99 (73%) | ||
| Fracture site | 0.456 | |||
| Intertrochanter | 251 (62%) | 79 (59%) | ||
| Femur Neck | 153 (38%) | 56 (41%) | ||
| Age (years) | 82.2 ± 6.3 | 82.0 ± 5.6 | 0.839 | |
| Body mass index (kg/m2) | 22.0 ± 3.6 | 21.5 ± 4.0 | 0.242 | |
| ASA grade | ||||
| II | 55 (16%) | 8 (6%) | ||
| III-IV | 349 (84%) | 127 (94%) | ||
| Anticoagulant medication | 114 (28%) | 52 (39%) | ||
| Aspirin | 70 | 32 | ||
| Clopidogrel | 36 | 16 | ||
| LMWH | 2 | 0 | ||
| Others | 6 | 4 | ||
| Time to operation (days) after admission | 3.2 ± 5.0 | 2.8 ± 3.5 | 0.218 | |
| Anesthesia | 0.322 | |||
| General | 198 (49%) | 73 (54%) | ||
| Spinal | 206 (51%) | 62 (46%) | ||
| Operation time (min) | 78.9±28.6 | 76.7±33.8 | 0.762 | |
| Length of hospital stay (days) | 22.7±12.4 | 17.4±8.5 | ||
Continuous variables are presented as mean±standard deviation.
ASA, American Society of Anesthesiologists; LMWH, low molecular weight heparin.
Comorbid medical diseases between the two groups.
| Characteristics | Control group | Study group | p-value |
|---|---|---|---|
| Cardiovascular diseases | 232 (57%) | 96 (71%) | |
| Pulmonary diseases | 26 (6%) | 15 (11%) | 0.076 |
| Endocrinologic diseases | 100 (25%) | 43 (32%) | 0.106 |
| Neurologic diseases | 97 (24%) | 48 (36%) | |
| Psychotic diseases | 19 (5%) | 7 (5%) | 0.821 |
| Cancer | 38 (9%) | 16 (12%) | 0.413 |
| Nephrologic diseases | 17 (4%) | 9 (7%) | 0.248 |
Fig 2Incidence of venous thromboembolism events and mortality between the two groups (*p < 0.05).
Comparison of VTE events between the two groups: Multivariate analysis*.
| Events | Control group | Study group | Odds ratio | p-value |
|---|---|---|---|---|
| Symptomatic DVT | 30 (7.4%) | 3 (2.2%) | 0.28 (0.08–0.95) | |
| Symptomatic PE | 15 (3.7%) | 2 (1.5%) | 0.39 (0.09–1.77) | 0.223 |
*Adjusted for ASA grade, cardiovascular disease, pulmonary disease, neurologic disease, and anticoagulant
medication at p <0.1 in univariate analyses.
VTE, venous thromboembolism; CI, confidence interval; DVT, deep vein thrombosis; PE, pulmonary embolism.